Palopegteriparatide (YORVIPATH) in Hypoparathyroidism National Drug Mini-monograph June 2025 VA Pharmacy Benefits Management Services and National Formulary Committee The purpose of VA …
YORVIPATH: First Hypoparathyroidism Treatment in Adults
Aug 16, 2024 · YORVIPATH is a prodrug of parathyroid hormone (PTH 1-34) administered once daily, designed to provide parathyroid hormone levels within the normal physiological range across the 24 …
Yorvipath for hypoparathyroidism – Hypoparathyroidism News
Aug 19, 2024 · Yorvipath, formerly TransCon PTH, is an approved daily injection treatment to manage blood calcium levels in adults with hypoparathyroidism.
FDA approves new drug for hypoparathyroidism, a rare disorder
The FDA has approved Yorvipath (palopegteriparatide) injection for subcutaneous use in adults with hypoparathyroidism. Yorvipath was not studied in adults with acute post-surgical hypoparathyroidism.
Preliminary results from a prospective cohort study on real-world data ...
This study presents preliminary results from an ongoing prospective cohort-study evaluating the real-world effectiveness of Yorvipath. Methods: Eligible patients were adults diagnosed with HypoPT who …
Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism ...
Oct 8, 2024 · TransCon PTH (palopegteriparatide, approved under the brand name YORVIPATH in the European Union and certain other countries as a replacement therapy indicated for the treatment of …
Chronic Hypoparathyroidism—Current and Emerging Therapies
Nov 1, 2025 · Conventional treatment for hypoparathyroidism with calcium salts and activated vitamin D has limitations such as inadequate control of symptomatic hypocalcemia and large pill burden. PTH …
Yorvipath for Hypoparathyroidism - HealthCentral
Jan 29, 2025 · What Does Research Show About Yorvipath for Hypoparathyroidism? The FDA approved Yorvipath based on evidence from a clinical trial involving 82 adults with chronic hypoparathyroidism.
PTH Replacement Therapies: Current Options and What’s Ahead
Jul 3, 2025 · The table below summarizes the three key therapies—Natpara, Forteo, and YORVIPATH—with attention to their origin, approval status, and role in clinical practice. Comparison …
Yorvipath Approved for Treatment of Hypoparathyroidism
Aug 16, 2024 · The Food and Drug Administration (FDA) has approved Yorvipath (palopegteriparatide; developed as TransCon PTH) for the treatment of hypoparathyroidism in adults. Yorvipath ® is a …